resectable pancreatic ductal adenocarcinoma Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 1 (1)

Interventional (1)

M.D. Anderson Cancer Center (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadceliac disease

I am/have/hadmetastasis

I am/have/hadpancreatic adenocarcinoma

I am/have/hadplatelet count

I am/have/hadneutrophil count

I am/have/hadcancer

I am/have/hadpancreatic cancer

I am/have/hadendoscopic ultrasound

I am/have/hadresectable pancreatic cancer

I am/have/hadadenocarcinoma

added new label for I am/have/had

more

I am looking for

I am looking forcisplatin

I am looking foroxaliplatin

I am looking foririnotecan

I am looking forgemcitabine

I am looking forleucovorin

I am looking forpaclitaxel

I am looking forfluorouracil

I am looking forcapecitabine

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

The purpose of this Phase I study is to determine the recommended phase 2 dose (RP2D) and safety profile of NBTXR3 activated by radiation therapy for the treatment of patients with pancreatic cancer that has spread to nearby tissues or lymph nodes (locally advanced) or may be able to be …

celiac disease

cisplatin

irinotecan

gemcitabine

pancreatic cancer

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.